Piracetam 吡拉西坦

CAS 7491-74-9 MFCD00079246

化学结构图

7491-74-9
SMILES: NC(=O)CN1CCCC1=O

化学属性

Mol. FormulaC6H10N2O2
Mol. Weight142.16
Appearance 白色结晶性粉末。熔点151.5-152.5℃。易溶于水,略溶于乙醇,几乎不溶于乙醚。无臭,味微苦。
Melting Point151-152°C
Boiling Point408.3°C at 760 mmHg
Flash Point200.8°C

别名和识别编码

Chemical NamePiracetam
CAS Number7491-74-9
Synonym Piracetam {LY} Piracetam {} {LY} Piracetam {} {} {LY} Piracetam {} {} {} {LY} Piracetam {} {} {} {} {LY} Piracetam {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Piracetam {} {} {} {} {} {} {} {} {} {} {} {} {} {}
MDL NumberMFCD00079246
PubChem Substance ID4843
EC Number231-312-7
Chemical Name Translation吡拉西坦
Wiswesser Line NotationT5NVTJ A1VZ
Beilstein Registry Number1526393
LabNetwork Molecule IDLN00194990
InChIInChI=1S/C6H10N2O2/c7-5(9)4-8-3-1-2-6(8)10/h1-4H2,(H2,7,9)
Canonical SMILESO=C(N)CN1C(CCC1)=O
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SNA} Bioactive Small Molecule Alphabetical Index, Neurobiology, Neuroscience, Nootropics, PI-PY, Pharmacologicals, 生物活性小分子, 细胞信号转导和神经科学, 细胞生物学
  • {SNA} Bioactive Small Molecules, Cell Biology,
  • Heterocycles
  • {SNA} Bioact
  • Pharmaceuticals
  • Intermediates & Fine Chemicals
  • {SNA} Bioactive Small Molecules, Cell Signaling a

产品应用

  • Nootropic.

相关文献及参考

  • Gobert, J., et al.: J. Pharm. Belg., 27, 281 (1972),
  • Oosterveld, W.J., et al.: Arzneim.-Forsch., 30, 1947 (1980),
  • Chouinard, G., et al.: Psychopharmacol. Bull., 17, 129 (1981),

安全信息

RTECSUX9660500
WGK Germany2
Personal Protective Equipment Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
GHS Symbol
Safety Statements
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : >10 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   PCJOAU Pharmaceutical Chemistry Journal (English Translation).  Translation
   of KHFZAN. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013)  No.1-
   1967-  Volume(issue)/page/year: 23,795,1989

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : >12 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   KHFZAN Khimiko-Farmatsevticheskii Zhurnal.  Chemical Pharmaceutical Journal.
    For English translation, see PCJOAU.  (V/O Mezhdunarodnaya Kniga, 113095
   Moscow, USSR)  V.1-    1967-  Volume(issue)/page/year: 11(8),132,1977

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Mammal - cat
DOSE/DURATION           : 10 gm/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   RPTOAN Russian Pharmacology and Toxicology (English Translation).
   Translation of FATOAO.  (Euromed Pub., 33, Woodlands Rd., Surbiton, Surrey,
   UK)  V.30-    1967-  Volume(issue)/page/year: 47,205,1984

TYPE OF TEST

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Oral
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 5600 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   FRPPAO Farmaco, Edizione Pratica. (Casella Postale 227, 27100 Pavia, Italy)
   V.8-43    1953-88 For publisher information, see FRMCE8
   Vol

Precautionary statements
Hazard statements
Storage condition 2-8°C {LY} 2-8°C {} {LY} 2-8°C {} {} {LY} 2-8°C {} {} {} {LY} 2-8°C {} {} {} {} {LY} 2-8°C {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {

其他信息

  • 用途二:早期用材林于抗眩晕和止吐药,目前作为神经系统药物,有促进和增强大脑记乙功能的作用,对老年性记忆减退有效。对某些低智能儿的智力提高胶,对老年性痴呆、脑外伤引起的记忆和思维障碍亦有一定疗效。
  • 下游产品:左乙拉西坦
  • 中枢神经兴奋药:吡拉西坦又称脑复康、吡乙酰胺、乙酰胺吡咯环酮,是一种脑代谢改善药物,属于γ-氨基丁酸的环化衍生物,对中枢作用选择性强,仅限于脑功能(记忆、意识等)的改善,精神兴奋作用弱,无精神药物的副作用,无依赖性。可预防或保护动物因缺氧而导致的逆行性健忘,亦能明显拮抗巴比妥盐对中枢的抑制作用,能促进脑细胞代谢,增加大脑对氨基酸、蛋白质、葡萄糖的吸收和利用,具有激活、保护和修复大脑神经细胞的作用,能促使脑内ADP转化为ATP,改善脑内代谢能量供应状况。它影响胆碱能神经元兴奋传递,促进乙酰胆碱合成。吡拉西坦可以抵抗物理因素和化学因素所致的脑功能损害,改善学习、记忆和回忆能力。可以改善由缺氧所造成的逆行性遗忘。口服易吸收,30~40分钟后血药浓度达峰值,蛋白结合率为30%,清除半衰期4~6小时,易透过血脑屏障,到达脑和脑脊液。口服后不能由肝脏分解,以原形形式从尿和粪便中排泄。主要用于脑部疾病所致的记忆和思维障碍,儿童器质性痴呆和智力低下,对轻中度的老年性痴呆有一定的作用,但对重症者无效。对改善功能性大脑功能衰退症候群的症状也有一定的疗效。吡拉西坦也可用于脑炎、一氧化碳、农药及酒精中毒的意识恢复,可用静注或滴注。
  • MSDS 信息:Piracetam(7491-74-9).msds
  • MOL 文件:7491-74-9.mol
  • 上游原料:甲醇钠 --> 氯乙酸乙酯 --> 氯乙酸甲酯 --> 2-吡咯烷酮
  • 用途一:用于脑动脉硬化症及脑血管意外所致的记忆和思维功能减退的治疗
  • 方法一:以2-吡咯烷酮为起始原料,在甲苯中与甲醇钠成盐,与氯代乙酸乙酯缩合后再氨化制得。
  • Sigma Aldrich:7491-74-9(sigmaaldrich)

系列性分类


相关产品推荐